Summit Securities Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Summit Securities Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,500	Closed	-$3.63M	–	1503
2025 Q1	$3.63M	Buy	+27,500	New	+$3.43M	0.57%	21
2022 Q1	–	Sell	-1,000	Closed	-$52K	–	1412
2021 Q4	$52K	Buy	+1,000	New	+$42K	﹤0.01%	726
2020 Q1	–	Sell	-3,500	Closed	-$12M	–	512
2019 Q4	$12M	Hold	3,500	–	–	0.91%	24
2019 Q3	$2.62M	Buy	+3,500	New	+$33.6K	0.23%	71

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Summit Securities Group's ITCI Position: Q3 2024 in Review

Summit Securities Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 816 shares — an estimated $56K sold.

Summit Securities Group first reported a position in ITCI in Q2 2019 and held it in 2 quarters. The position peaked at $594K in Q2 2019. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Summit Securities Group reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Summit Securities Group sold 816 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $56K.
Summit Securities Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and held it in 2 quarters.
Summit Securities Group's Intra-Cellular Therapies Inc. position peaked at $594K in Q2 2019.
354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Summit Securities Group's 13F filing for Q3 2024, filed 7 Nov 2024.